2Dubertret L, Murrieta Aguttes M, Toner J. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with lorata dine in chronic idiopathic urticaria: results of the MILOR Study[J].J Eur Acad Dermatol Venereol, 1999, 12(1): 16-24.
1[1]Soter NA, Lewis RA, Corey EJ, et al. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin[J]. J Invest Dermatol, 1983, 80(2): 115-119.
2[2]Koro O, Furutani K, Hide M, et al. Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis [J]. J Allergy Clin Immunol, 1999, 103(4): 663-670.
3[3]Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebocontrolled, crossover clinical study[J]. J Allergy Clin Immunol,2002, 110(3): 484-488.
4[4]Pichat P, Angel I, Arbilla S. Anti-inflammatory properties of mizolastine after oral administration on arachidonie acid-induced cutaneous reaction in the rat[J]. Arzneimittelforschung, 1998, 48(2): 173-178.
5[5]Selloum L, Bouriche H, Tigrine C, et al. Anti-inflammatory effect of rutin on rat paw oedema, and on neutrophils ehemotaxis and degranulation[J]. Exp Toxicol Pathol, 2003, 54(4): 313-318.
6[6]Yamada N, Fanayama K. Inhibitory effects of mizolastine on the release of mediators and antagonistic effects against mediators[J].Jpn Pharmacol Ther, 1998, 26(2): 131-138.
